Mavacamten has made headlines this year, being the first medication to show
positive results in treating hypertrophic cardiomyopathy (HCM). HCM is a
heart-disease in which the heart muscle thickens. This puts extra stress on
the heart, potentially leading to cardiac arrest down the line. With a
mortality rate below ~1% per year, this is not a huge problem in most
cases, but in cases where it is, invasive, potentially dangerous, measures
have to be taken.Mavacamten changes this. The new medication reduces abnormal
contractions caused by genetic variants, targeting the underlying condition
directly. Previously, doctors had to treat individual symptoms caused by
HCM one by one, oftentimes using a multitude of medications like beta
blockers, antiarrhythmic drugs, calcium channel blockers and others.
With Mavacamten there is no need for this cocktail of ingredients
anymore, a study revealed.
positive results in treating hypertrophic cardiomyopathy (HCM). HCM is a
heart-disease in which the heart muscle thickens. This puts extra stress on
the heart, potentially leading to cardiac arrest down the line. With a
mortality rate below ~1% per year, this is not a huge problem in most
cases, but in cases where it is, invasive, potentially dangerous, measures
have to be taken.Mavacamten changes this. The new medication reduces abnormal
contractions caused by genetic variants, targeting the underlying condition
directly. Previously, doctors had to treat individual symptoms caused by
HCM one by one, oftentimes using a multitude of medications like beta
blockers, antiarrhythmic drugs, calcium channel blockers and others.
With Mavacamten there is no need for this cocktail of ingredients
anymore, a study revealed.
If there is no precise treatment, many patients are dependent on a
multitude of drugs combating their symptoms.
